Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis

Rajput A, Poudel S, Tsunemoto H, Meehan M, Szubin R, Olson CA, Seif Y, Lamsa A, Dillon N, Vrbanac A. Identifying the effect of vancomycin on health care–associated methicillin-resistant Staphylococcus aureus strains using bacteriological and physiological media. GigaScience. 2021;10(1):giaa156.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Panwala T, Gandhi P, Jethwa D: Inducible Clindamycin resistance and MRSA amongst Staphylococcus aureus isolates: A phenotypic detection.

Thabit AK, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of telavancin against methicillin-susceptible and-resistant Staphylococcus aureus with and without prior vancomycin exposure. Antimicrob Agents Chemother. 2016;60(1):222–8.

CAS  PubMed  Article  Google Scholar 

Cascioferro S, Carbone D, Parrino B, Pecoraro C, Giovannetti E, Cirrincione G, Diana P. Therapeutic strategies to counteract antibiotic resistance in MRSA biofilm-associated infections. ChemMedChem. 2021;16(1):65–80.

CAS  PubMed  Article  Google Scholar 

Appelbaum PJCM. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006;12:16–23.

CAS  PubMed  Article  Google Scholar 

Selvabai, AP, Sattar, SBA, Jayaraman, P, SHANMUGAM PJJoC, Research D. Detection and Characterisation of Heteroresistant Vancomycin Intermediate Staphylococcus aureus (hVISA) using Phenotypic and Genotypic Methods. J Clin Diagn Res. 2019. https://doi.org/10.7860/JCDR/2019/41127.12868.

Article  Google Scholar 

Wu Q, Sabokroo N, Wang Y, Hashemian M, Karamollahi S, Kouhsari EJAR, Control I. Systematic review and meta-analysis of the epidemiology of vancomycin-resistance Staphylococcus aureus. Isolates Antimicrob Resist Infect Control. 2021;10(1):1–13.

Article  Google Scholar 

Frank AL, Marcinak JF, Mangat PD, Tjhio JT, Kelkar S, Schreckenberger Quinn PC, JPJTPidj,. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatric Infect Dis J. 2002;21(6):530–4.

Article  Google Scholar 

Blair J, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJJNrm. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51.

CAS  PubMed  Article  Google Scholar 

Chambers HJPm. Methicillin-resistant Staphylococcus aureus. Mechanisms of resistance and implications for treatment. 2001;109(2 Suppl):43–50.

CAS  Google Scholar 

GM Eliopoulos VG Meka 2004 Gold HSJCID: Antimicrobial resistance to linezolid 39 7 1010 1015

Lewis JS, Jorgensen JHJCID. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis. 2005;40(2):280–5.

PubMed  Article  Google Scholar 

Al Jalali V, Zeitlinger M. Clinical pharmacokinetics and pharmacodynamics of telavancin compared with the other glycopeptides. Clin Pharmacokinet. 2018;57(7):797–816.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Saravolatz LD, Stein GE. Oritavancin: a long-half-life lipoglycopeptide. Clin Infect Dis. 2015;61(4):627–32.

CAS  PubMed  Article  Google Scholar 

Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis. 2017;49(7):483–92.

Article  Google Scholar 

Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. New lipoglycopeptides. Drugs. 2010;70(7):859–86.

CAS  PubMed  Article  Google Scholar 

Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54(3):S214–9.

CAS  PubMed  Article  Google Scholar 

Song Y, Lunde CS, Benton BM, Wilkinson BJ. Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies. Antimicrob Agents Chemother. 2012;56(6):3157–64.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, Parr TR, Moeck G. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54(12):5369–71.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis. 2015;61(8):1315–21.

CAS  PubMed  Article  Google Scholar 

Chen K-H, Huang Y-T, Liao C-H, Sheng W-H, Hsueh P-R. In vitro activities of tedizolid and linezolid against Gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia. Antimicrob Agents Chemother. 2015;59(10):6262–5.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mikamo H, Takesue Y, Iwamoto Y, Tanigawa T, Kato M, Tanimura Y, Kohno S. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan–results of a randomised, multicentre phase 3 study. J Infect Chemother. 2018;24(6):434–42.

CAS  PubMed  Article  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). Journal of Chinese Integrative Medicine. 2009 Sep;7(9):889–96.

Newcastle O: Newcastle-Ottawa: Scale customized for cross-sectional studies In. In.; 2018.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

CAS  PubMed  Article  Google Scholar 

Abdel-Wahab FB, El Menofy N, El-Batal A, Mosalam F, Abdulall AK. Enhanced Antimicrobial Activity of the combination of Silver Nanoparticles and Different β Lactam antibiotics against Methicillin Resistant Staphylococcus aureus isolates. Azhar Int J Phar Med Sci. 2021;1(1):24–33.

Article  Google Scholar 

Bradley JS. Which antibiotic for resistant gram-positives, and why? J Infect. 2014;68:S63–75.

PubMed  Article  Google Scholar 

Hadadi M, Heidari H, Ebrahim-Saraie HS, Motamedifar M. Molecular characterization of vancomycin, mupirocin and antiseptic resistant Staphylococcus aureus strains. Mediter J Hematol Infect Dis. 2018;10(1):e2018053.

Article  Google Scholar 

Lee C-R, Cho IH, Jeong BC, Lee SH. Strategies to minimize antibiotic resistance. Int J Environ Res Public Health. 2013;10(9):4274–305.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wu Q, Sabokroo N, Wang Y, Hashemian M, Karamollahi S, Kouhsari E. Systematic review and meta-analysis of the epidemiology of vancomycin-resistance Staphylococcus aureus isolates. Antimicrob Resist Infect Control. 2021;10(1):1–13.

Article  Google Scholar 

!!! INVALID CITATION !!! (9, 24–26).

Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK. Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from US medical centers. Antimicrob Agents Chemother. 2018;62(3):e20397.

Article  Google Scholar 

Esposito S, Purrello Sm, Bonnet E, Novelli A, Tripodi F, Pascale R, Unal S, Milkovich G. Central venous catheter-related biofilm infections: An up-to-date focus on meticillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2013;1(2):71–8.

CAS  PubMed  Article  Google Scholar 

Di Pilato V, Ceccherini F, Sennati S, D’Agostino F, Arena F, D’Atanasio N, Di Giorgio FP, Tongiani S, Pallecchi L, Rossolini GM. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp biofilms over prolonged exposure times. Diagn Microbiol Infect Dis. 2020;96(2):114901.

PubMed  Article  CAS  Google Scholar 

Guest JF, Esteban J, Manganelli AG, Novelli A, Rizzardini G, Serra M. Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: results of a network meta-analysis. PLoS ONE. 2017;12(11):e0187792.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Activity of oritavancin against gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010–13). J Antimicrob Chemother. 2015;70(2):498–504.

CAS  PubMed  Article  Google Scholar 

Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR. Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials. InOpen forum infectious diseases. 2017 Jan 1;4;1. Oxford University Press.

Hasannejad-Bibalan M, Mojtahedi A, Biglari H, Halaji M, Sedigh Ebrahim-Saraie H. Antibacterial activity of tedizolid, a novel oxazolidinone against methicillin-resistant Staphylococcus aureus: a systematic review and meta-analysis. Microb Drug Resist. 2019;25(9):1330–7.

CAS  PubMed  Article  Google Scholar 

Biedenbach D, Bouchillon S, Johnson B, Alder J, Sahm D. In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China. Eur J Clin Microbiol Infect Dis. 2016;35(12):1933–9.

CAS  PubMed  Article  Google Scholar 

Betriu C, Morales G, Rodríguez-Avial I, Culebras E, Gómez M, López-Fabal F, Picazo JJ. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother. 2010;54(5):2212–5.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. J Antimicrob Chemother. 2016;71(1):152–5.

CAS  PubMed  Article  Google Scholar 

Moenster RP, Linneman TW, Call WB, Kay CL, McEvoy TA, Sanders JL. The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults. J Clin Pharm Ther. 2013;38(2):89–96.

CAS  PubMed  Article  Google Scholar 

Lee EY, Caffrey AR. Thrombocytopenia with tedizolid and linezolid. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/AAC.01453-17.

Article  PubMed  PubMed Central 

留言 (0)

沒有登入
gif